{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,4]],"date-time":"2025-10-04T21:44:05Z","timestamp":1759614245031,"version":"build-2065373602"},"reference-count":34,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,4,4]],"date-time":"2025-04-04T00:00:00Z","timestamp":1743724800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["canadianjournalofophthalmology.ca","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Canadian Journal of Ophthalmology"],"published-print":{"date-parts":[[2025,10]]},"DOI":"10.1016\/j.jcjo.2025.03.020","type":"journal-article","created":{"date-parts":[[2025,5,2]],"date-time":"2025-05-02T23:32:32Z","timestamp":1746228752000},"page":"284-288","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Cost and availability of high-dose oral prednisone for management of optic neuritis"],"prefix":"10.1016","volume":"60","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7757-2141","authenticated-orcid":false,"given":"Afreen","family":"Ahmad","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4911-9152","authenticated-orcid":false,"given":"Jonathan A.","family":"Micieli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jcjo.2025.03.020_bib0001","doi-asserted-by":"crossref","first-page":"1236","DOI":"10.1212\/CON.0000000000000768","article-title":"Optic neuritis","volume":"25","author":"Bennett","year":"2019","journal-title":"Continuum (Minneap Minn)"},{"key":"10.1016\/j.jcjo.2025.03.020_bib0002","doi-asserted-by":"crossref","first-page":"1120","DOI":"10.1016\/S1474-4422(22)00200-9","article-title":"Diagnosis and classification of optic neuritis","volume":"21","author":"Petzold","year":"2022","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.jcjo.2025.03.020_bib0003","doi-asserted-by":"crossref","first-page":"2481","DOI":"10.1016\/S0140-6736(17)32346-2","article-title":"Clemastine fumarate as a remyelinating therapy for multiple sclerosis (ReBUILD): a randomised, controlled, double-blind, crossover trial","volume":"390","author":"Green","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/j.jcjo.2025.03.020_bib0004","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/S1474-4422(13)70259-X","article-title":"Optic neuritis","volume":"13","author":"Toosy","year":"2014","journal-title":"Lancet Neurol"},{"year":"2022","series-title":"Optic neuritis. In StatPearls [Internet]","author":"Guier","key":"10.1016\/j.jcjo.2025.03.020_bib0005"},{"key":"10.1016\/j.jcjo.2025.03.020_bib0006","series-title":"In StatPearls [Internet]","article-title":"Prednisone","author":"Puckett","year":"2023"},{"key":"10.1016\/j.jcjo.2025.03.020_bib0007","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1177\/87551225221116266","article-title":"Complications of corticosteroid therapy: a comprehensive literature review","volume":"38","author":"Koshi","year":"2022","journal-title":"J Pharm Technol"},{"key":"10.1016\/j.jcjo.2025.03.020_bib0008","doi-asserted-by":"crossref","first-page":"j1415","DOI":"10.1136\/bmj.j1415","article-title":"Short term use of oral corticosteroids and related harms among adults in the United States: population based cohort study","volume":"357","author":"Waljee","year":"2017","journal-title":"BMJ"},{"key":"10.1016\/j.jcjo.2025.03.020_bib0009","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1186\/s40780-024-00329-x","article-title":"An evaluation of pharmacists\u2019 general attitudes, knowledge, and phobias regarding medications that include corticosteroids: a cross-sectional study","volume":"10","author":"Barakat","year":"2024","journal-title":"J Pharm Health Care Sci"},{"key":"10.1016\/j.jcjo.2025.03.020_bib0010","doi-asserted-by":"crossref","DOI":"10.1016\/j.jsps.2023.101777","article-title":"Evaluation of knowledge, experiences, and fear toward prescribing and dispensing corticosteroids among Egyptian healthcare professionals: a cross-sectional study","volume":"31","author":"Barakat","year":"2023","journal-title":"Saudi Pharm J"},{"journal-title":"Pharmacy Connection","article-title":"Near miss highlights importance of therapeutic check during transitions of care [Internet]","year":"2023","key":"10.1016\/j.jcjo.2025.03.020_bib0011"},{"key":"10.1016\/j.jcjo.2025.03.020_bib0012","first-page":"E63","article-title":"The consequences of patient charges for prescription drugs in Canada: a cross-sectional survey","volume":"6","author":"Law","year":"2018","journal-title":"Can Med Assoc Open Access J"},{"key":"10.1016\/j.jcjo.2025.03.020_bib0014","doi-asserted-by":"crossref","first-page":"605","DOI":"10.7326\/M18-1138","article-title":"Variation in prescription drug prices by retail pharmacy type: a national cross-sectional study","volume":"171","author":"Luo","year":"2019","journal-title":"Ann Int Med"},{"key":"10.1016\/j.jcjo.2025.03.020_bib0015","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.jsps.2011.11.003","article-title":"Dispensing medications without prescription at Saudi community pharmacy: extent and perception","volume":"21","author":"Al-Mohamadi","year":"2013","journal-title":"Saudi Pharm J"},{"key":"10.1016\/j.jcjo.2025.03.020_bib0016","doi-asserted-by":"crossref","first-page":"19","DOI":"10.2165\/00148365-200806010-00002","article-title":"Differences in generic drug prices between the US and Canada","volume":"6","author":"Gooi","year":"2008","journal-title":"Appl Health Econ Health Pol"},{"key":"10.1016\/j.jcjo.2025.03.020_bib0017","unstructured":"City of Toronto. Community Council Area Profiles [Internet]. Toronto: City of Toronto; [cited 2024 Dec 21]. Available from:https:\/\/www.toronto.ca\/city-government\/data-research-maps\/neighbourhoods-communities\/community-council-area-profiles\/"},{"key":"10.1016\/j.jcjo.2025.03.020_bib0018","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1001\/jama.285.4.421","article-title":"Adverse events associated with prescription drug cost-sharing among poor and elderly persons","volume":"285","author":"Tamblyn","year":"2001","journal-title":"JAMA"},{"key":"10.1016\/j.jcjo.2025.03.020_bib0019","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1001\/jama.298.1.61","article-title":"Prescription drug cost sharing: associations with medication and medical utilization and spending and health","volume":"298","author":"Goldman","year":"2007","journal-title":"JAMA"},{"key":"10.1016\/j.jcjo.2025.03.020_bib0020","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1016\/j.healthpol.2019.12.007","article-title":"Socioeconomic differences in prescription drug supplemental coverage in Canada: a repeated cross-sectional study","volume":"124","author":"Guo","year":"2020","journal-title":"Health Policy"},{"year":"2023","series-title":"Optic neuritis. InStatPearls [Internet]","author":"Guier","key":"10.1016\/j.jcjo.2025.03.020_bib0021"},{"key":"10.1016\/j.jcjo.2025.03.020_bib0022","article-title":"Determinants of drug prices: a systematic review of comparison studies","volume":"11","author":"Daalen","year":"2021","journal-title":"BMJ Open"},{"key":"10.1016\/j.jcjo.2025.03.020_bib0023","doi-asserted-by":"crossref","DOI":"10.1155\/2015\/547960","article-title":"Comparison of United States and Canadian glaucoma medication costs and price change from 2006 to 2013","volume":"2015","author":"Schlenker","year":"2015","journal-title":"J Ophthalmol"},{"key":"10.1016\/j.jcjo.2025.03.020_bib0024","doi-asserted-by":"crossref","first-page":"1358","DOI":"10.1016\/j.ophtha.2019.04.018","article-title":"Comparison of United States and international ophthalmic drug pricing","volume":"126","author":"Gong","year":"2019","journal-title":"Ophthalmology"},{"key":"10.1016\/j.jcjo.2025.03.020_bib0025","article-title":"Ophthalmic medication price variation across the United States: anti-inflammatory medications","volume":"11","author":"Scott","year":"2019","journal-title":"Ther Adv Ophthalmol"},{"key":"10.1016\/j.jcjo.2025.03.020_bib0026","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/j.jcjo.2017.08.003","article-title":"Comparative cost evaluation of brand name and generic ophthalmology medications in Ontario","volume":"53","author":"Popovic","year":"2018","journal-title":"Can J Ophthalmol"},{"year":"2020","series-title":"Highlights of hospital spending in Canada, 2020 [Internet]","key":"10.1016\/j.jcjo.2025.03.020_bib0027"},{"year":"2024","series-title":"Why a pharmacist won\u2019t fill your prescription\u2014and what you can do [Internet]","key":"10.1016\/j.jcjo.2025.03.020_bib0028"},{"key":"10.1016\/j.jcjo.2025.03.020_bib0029","unstructured":"College of Physicians and Surgeons of Ontario. Dispensing Drugs [Internet]. Toronto (ON): CPSO; [cited 2024 Dec 10]. Available from:https:\/\/www.cpso.on.ca\/Physicians\/Policies-Guidance\/Policies\/Dispensing-Drugs?utm_source=chatgpt.com"},{"key":"10.1016\/j.jcjo.2025.03.020_bib0030","doi-asserted-by":"crossref","first-page":"qxad003","DOI":"10.1093\/haschl\/qxad003","article-title":"Role of independent versus chain pharmacies in providing pharmacy access: a nationwide, individual-level geographic information systems analysis","volume":"1","author":"Hernandez","year":"2023","journal-title":"Health Affairs Scholar"},{"key":"10.1016\/j.jcjo.2025.03.020_bib0031","doi-asserted-by":"crossref","first-page":"412","DOI":"10.2471\/BLT.10.084327","article-title":"Differences in the availability of medicines for chronic and acute conditions in the public and private sectors of developing countries","volume":"89","author":"Cameron","year":"2011","journal-title":"Bull World Health Organ"},{"key":"10.1016\/j.jcjo.2025.03.020_bib0032","doi-asserted-by":"crossref","first-page":"605","DOI":"10.7326\/M18-1138","article-title":"Variation in prescription drug prices by retail pharmacy type: a national cross-sectional study","volume":"171","author":"Luo","year":"2019","journal-title":"Ann Int Med"},{"key":"10.1016\/j.jcjo.2025.03.020_bib0033","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/1476-072X-11-48","article-title":"Medication deserts: survey of neighborhood disparities in availability of prescription medications","volume":"11","author":"Amstislavski","year":"2012","journal-title":"Int J Health Geogr"},{"key":"10.1016\/j.jcjo.2025.03.020_bib0034","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1056\/NEJM199202273260901","article-title":"A randomized, controlled trial of corticosteroids in the treatment of acute optic neuritis","volume":"326","author":"Beck","year":"1992","journal-title":"New Engl J Med"},{"key":"10.1016\/j.jcjo.2025.03.020_bib0035","doi-asserted-by":"crossref","DOI":"10.1002\/brb3.1032","article-title":"Time to steroid treatment in severe acute optic neuritis","volume":"8","author":"Dale","year":"2018","journal-title":"Brain Behav"}],"container-title":["Canadian Journal of Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0008418225001498?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0008418225001498?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,4]],"date-time":"2025-10-04T21:21:26Z","timestamp":1759612886000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0008418225001498"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10]]},"references-count":34,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2025,10]]}},"alternative-id":["S0008418225001498"],"URL":"https:\/\/doi.org\/10.1016\/j.jcjo.2025.03.020","relation":{},"ISSN":["0008-4182"],"issn-type":[{"type":"print","value":"0008-4182"}],"subject":[],"published":{"date-parts":[[2025,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Cost and availability of high-dose oral prednisone for management of optic neuritis","name":"articletitle","label":"Article Title"},{"value":"Canadian Journal of Ophthalmology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jcjo.2025.03.020","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Inc. on behalf of Canadian Ophthalmological Society.","name":"copyright","label":"Copyright"}]}}